SOPHiA GENETICS (SOPH) Common Equity (2020 - 2025)

SOPHiA GENETICS's Common Equity history runs 6 years deep, the most recent figure standing at $47.1 million for Q4 2025.

• In Q4 2025, Common Equity fell 51.14% year-over-year to $47.1 million; the TTM figure through Dec 2025 stood at $47.1 million (down 51.14% YoY), while the FY2025 annual figure was $47.1 million, down 51.14% from the prior year.
• Common Equity came in at $47.1 million for Q4 2025 at SOPHiA GENETICS, down from $60.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $289.7 million in Q3 2021 to a low of $47.1 million in Q4 2025.
• A 5-year average of $153.8 million and a median of $151.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 220.86% in 2022 and plunged 51.14% in 2025, its largest moves.
• SOPHiA GENETICS's Common Equity stood at $275.4 million in 2021, then decreased by 27.33% to $200.1 million in 2022, then slipped by 24.33% to $151.4 million in 2023, then plunged by 36.29% to $96.5 million in 2024, then tumbled by 51.14% to $47.1 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $47.1 million, $60.7 million, and $76.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison